Century Therapeutics (IPSC) Operating Expenses (2022 - 2025)
Historic Operating Expenses for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $36.1 million.
- Century Therapeutics' Operating Expenses rose 152.89% to $36.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.2 million, marking a year-over-year decrease of 4.55%. This contributed to the annual value of $144.7 million for FY2024, which is 272.55% down from last year.
- Century Therapeutics' Operating Expenses amounted to $36.1 million in Q3 2025, which was up 152.89% from $34.7 million recorded in Q2 2025.
- Century Therapeutics' 5-year Operating Expenses high stood at $44.0 million for Q4 2023, and its period low was $32.2 million during Q1 2024.
- Over the past 4 years, Century Therapeutics' median Operating Expenses value was $35.2 million (recorded in 2023), while the average stood at $35.9 million.
- Over the last 5 years, Century Therapeutics' Operating Expenses had its largest YoY gain of 3016.23% in 2023, and its largest YoY loss of 1219.15% in 2023.
- Quarter analysis of 4 years shows Century Therapeutics' Operating Expenses stood at $33.8 million in 2022, then surged by 30.16% to $44.0 million in 2023, then fell by 5.84% to $41.5 million in 2024, then fell by 12.86% to $36.1 million in 2025.
- Its Operating Expenses was $36.1 million in Q3 2025, compared to $34.7 million in Q2 2025 and $35.0 million in Q1 2025.